Navigation Links
MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Date:3/24/2008

ompared to the currently marketed conventional nebulized budesonide," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "These results are consistent with our previous clinical studies, and we believe provide additional support for the safety of our next generation pediatric asthma therapy."

The company plans to present the results from this study at a future scientific conference.

About Unit Dose Budesonide

MAP Pharmaceuticals is developing Unit Dose Budesonide, a novel version of nebulized budesonide for treating pediatric asthma in children from 12 months to eight years of age. Budesonide is an inhaled corticosteroid that has been used for more than 20 years with demonstrated safety and efficacy. It is the only corticosteroid approved for treating asthma in pregnant women and in children as young as 12 months old. UDB is designed to be administered more quickly and to provide efficacy at a lower corticosteroid label dose than the commercially available product.

About Pediatric Asthma

Of the estimated 20 million diagnosed asthma patients in the United States, approximately 6.8 million are children under 18 years of age and approximately 1.2 million are children under five years of age. Guidelines released in 2007 recommend the prophylactic use of inhaled corticosteroids (ICS) as the preferred initial treatment to reduce inflammation and maintain long-term control of asthma in children of all ages.

In the United States, children under the age of five typically use a nebulizer to receive inhaled corticosteroid medication because they lack the breath coordination needed to use pressurized metered-dose inhalers or they lack the lung capacity needed to use dry powder inhalers. The current goal of asthma management is, with proper treatment, to allow children with asthma to lead active lives.

Since the introduction of conventional nebulized budesonide, annual sales have grown to approxi
'/>"/>

SOURCE MAP Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015   Bernstein Liebhard LLP is ... the "Company") (NASDAQ: AERI ) issued materially ... of the federal securities laws; or (ii) the ... duties to shareholders. Aerie is a ... and commercialization of first-in-class therapies for the treatment ...
(Date:4/24/2015)... 24, 2015  A new study shows an "alarming rise" ... used to slow the progression of multiple sclerosis or reduce ... researchers at Oregon Health & Science University (OHSU) and Oregon ... number of MS drugs in the marketplace over the past ... costs for patients who use those drugs. Researchers found the ...
(Date:4/24/2015)... --  Vestagen Technical Textiles, Inc. today announced that ... received two notable innovation awards. The first is the ... with potential to create a positive impact in the ... New York City , VESTEX received the Silver ... category. The awards honor excellence in new product and ...
Breaking Medicine Technology:Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Aerie Pharmaceuticals, Inc. 2Researchers find alarming rise in cost of MS drugs over past two decades 2Researchers find alarming rise in cost of MS drugs over past two decades 3Researchers find alarming rise in cost of MS drugs over past two decades 4VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3
... 2011 Abaxis, Inc. (NasdaqGS: ABAX), a medical products company ... to discuss its financial results for the second quarter of ... be at 4:15 p.m. ET on Tuesday, October 25, 2011. ... of fiscal year 2012 after the market closes on Tuesday, ...
... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a specialty ... on Monday, October 31, 2011 before the opening of the ... call that day at 10:00 a.m. ET to discuss results ... to be used during the call will be available on ...
Cached Medicine Technology:Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 3
(Date:4/25/2015)... April 26, 2015 The National ... , a national endeavor to prepare nurses to provide ... a great success, according to a new report by ... original funding partners. , The project began in ... (CCP), under the direction of Elaine Tagliareni, EdD, RN, ...
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair of ... statement following the deadly earthquake in Nepal: , "Today ... the deaths of more than 1,000 people. The ... Bangladesh, India and other parts of South Asia. ... people of Nepal and the families of the victims. ...
(Date:4/25/2015)... 2015 By definition, a CIO’s responsibility is ... enterprise relying on their judgement and expertise to keep digital ... to an article published in National Mortgage News on ... doing a disservice to their responsibilities by focusing too heavily ... are crossed when it comes to company policy and industry ...
(Date:4/25/2015)... Parker and Sons projects growth in 2015. ... in Arizona alongside the growing economy. As a result, Parker ... April to help account for the rising need for heating, ... is something we are enthusiastic about. It means growth for ... at Parker and Sons. , Indeed, Parker and Sons has ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
Breaking Medicine News(10 mins):Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2
... NEW YORK, June 10 Tongji Healthcare, Inc.,(OTC Bulletin ... in China, reports that its hospital are enjoying an,influx ... province., Due to its status as a private ... Beijing that he has suggested the government would,pick up ...
... As nearly 80 percent of adults,experience back pain ... Carolina this month will launch a free, back care ... of the most common medical problems and affects eight,out ... In South Carolina, back,disorders were among the top causes ...
... of patients with testicular cancer are cured nowadays, but ... survivors, the medical profession and national governments, a cancer ... on Teenage and Young Adult Cancer Medicine, which is ... and 10). , Dr Craig Nichols, director of program ...
... The Endocrine Society will present Ronald S. ... Biomedical Research Institute at Harbor-UCLA Medical Center (LA ... annual convention June 15-18 in San Francisco. , ... members representing the full range of disciplines associated ...
... But their tech savvy helps them use online programs ... June 10 (HealthDay News) -- Insomnia among U.S. combat ... seen in patients with chronic insomnia, according to University ... post-deployment adjustment disorders to 14 insomnia patients and 14 ...
... Mylan Inc. (NYSE: MYL ),announced today ... agreement with,NATCO Pharma Ltd. (NATCO) for NATCO,s glatiramer ... which is used to treat,multiple sclerosis. The agreement ... and all major markets in Europe, Australia, New,Zealand, ...
Cached Medicine News:Health News:Tongji Healthcare Services Reports Influx of Patients 2Health News:BlueChoice HealthPlan to Launch Back Care Program 2Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 2Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 3Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 4Health News:LA BioMed investigator wins Distinguished Educator Award 2Health News:Combat Vets Display Severe Sleep Disorders 2Health News:Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R) 2
The Guidant Fineline EZ leads with protective capsule are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing....
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... The Model 6491 unipolar ... designed for temporary atrial and ... and after cardiac surgery. This ... downsized, making it the ideal ...
... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
Medicine Products: